Phantom Pain and Psilocybin

March 29, 2024 Lynne Nardizzi

Phantom pain and psilocybin are a growing area of research.

Psilocybin may be a treatment for this debilitating condition in the future.

Psilocybin for Anxiety

March 12, 2024 Lynne Nardizzi

A new study has shown a remarkable clinical reduction in anxiety with psilocybin-assisted therapy, four times greater than the placebo group.

Also the trial’s rate of full remission, or a full cessation of symptoms, was five times greater than the placebo group, a marked and compelling difference in treatment outcomes.

Serotonin Toxicity, Psilocybin and Anti-depressants

March 8, 2024 Lynne Nardizzi

In a case report published in the journal Primary Care Companion to Central Nervous System Disorders, three Penn State clinicians describe a patient who experienced serotonin toxicity after combining antidepressants and anti-anxiety medications and psilocybin.

Serotonin toxicity, or serotonin syndrome, occurs when high levels of serotonin build up on the body; the condition can be fatal.

The Benefits of Psilocybin

March 3, 2024 Lynne Nardizzi

Small clinical trials have shown that one or two doses of psilocybin, given in a therapeutic setting, can make dramatic and long-lasting changes in people suffering from treatment-resistant major depressive disorder, which typically does not respond to traditional antidepressants.

Click here for the link to this article.

Next-Gen Psilocybin

December 6, 2023 Lynne Nardizzi

Cybin, a biotech company working on next-generation psychedelic treatments, announced remarkable results from its Phase 2 clinical trial using a proprietary version of deuterated psilocybin for the treatment of depression.

CYB003 is a next-generation psilocybin designed to provide a faster onset of action and to reduce the duration of effects, ultimately thinning the financial barrier to access of this medicine in a medical setting.

The trial’s interim data demonstrated “rapid, robust, and clinically significant reduction of depression symptoms” three weeks after a single 12mg dose of CYB003.

Psilocybin and Adverse Childhood Experiences

October 23, 2023 Lynne Nardizzi

In this new study, findings suggest that psilocybin therapy may be potentially acceptable and may feasibly help in supporting survivors of adverse childhood experiences with particularly strong benefits to those with more severe childhood adversity.

New Psilocybin Research

September 25, 2023 Lynne Nardizzi

This recently published study showed that psilocybin use is associated with persisting improvements in mental health and wellbeing.

Psilocybin, Cancer and Depression

August 16, 2023 Lynne Nardizzi

The HOPE trial (A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients with Cancer) is an Institutional Review Boards-approved open-label feasibility and safety pilot study examining psilocybin-assisted group therapy in cancer patients with a DSM-5 depressive disorder (including major depressive disorder as well as adjustment disorder with depressed mood).

This pilot study demonstrated the safety, feasibility, and possible efficacy of psilocybin-assisted group therapy for cancer patients dealing with depressive symptoms.

Psilocybin-based Treatment Combined with Therapy

August 8, 2023 Lynne Nardizzi

A major new study has found that psilocybin-based treatment combined with therapy may provide more cost-effective solution to treating depression than methods such as CBT.

Oregon’s First Psilocybin Client!

July 31, 2023 Lynne Nardizzi

Keep reading for an interview with the patient thought to be the first person to receive psilocybin under Oregon’s new system. He discusses his psilocybin experience.

Psilocybin and Music

May 23, 2023 Lynne Nardizzi

Psilocybin therapy for depression appears to have a curious effect on the brain’s response to music.

Blog